ArticleJournal of mammary gland biology and neoplasia2026
COX-2- and IDO-associated immunomodulatory functions of stage II carcinoma-associated fibroblasts in breast cancer.
Article in Journal of mammary gland biology and neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The immune response against cancer is influenced by the tumor stroma. Carcinoma-associated fibroblasts (CAFs), a significant part of the stroma, are important modulators of the tumour microenvironment (TME). The current study examined the immunomodulatory properties of CAFs isolated from a stage II mouse model of mammary invasive ductal cancer. Based on the expression of surface markers, we described Stage II CAFs and assessed their effects on cytokine release, nitric oxide (NO) generation, and splenocyte proliferation in direct co-culture systems. Class II MHC molecules (I-Ad/I-Ed), FAP-1, CD29, CD90, and CD105 were all expressed by isolated CAFs, indicating the possibility of direct immunological contact. In direct co-culture, CAFs demonstrated two distinct functions: their conditioned medium (CM) had immunosuppressive effects, whereas direct cell interactions promoted splenocyte growth. Additionally, CAFs changed the cytokine milieu, particularly by secreting high levels of TGF-β and PGE₂, and dramatically reduced splenocyte NO generation. COX-2, IDO, and MMP2 were significantly upregulated in CAFs, according to gene expression data. Our results emphasize the potential of Stage II CAFs as a therapeutic target in breast cancer by demonstrating their complex immunomodulatory character, which includes the ability to both stimulate and repress immune responses through cellular contact and soluble factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.